Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.42 |
| ▸ | CCR5 | P51681 | 2/20 | 0.42 |
| ▸ | CCR8 | P51685 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.34 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7920736 | 0.79 | CCR1 (0.45) | CCR1CCR5CCR8CYP1A2IKBKB | |
| SCHEMBL8310528 | 0.71 | NPC1 (0.32) | GAA | |
| SCHEMBL18342663 | 0.69 | EGFR (0.33) | — | |
| SCHEMBL23846490 | 0.69 | IKBKB (0.51) | CCR1CCR5CCR8IKBKBKDM4E | |
| SCHEMBL14232405 | 0.67 | IKBKB (0.53) | CCR1CCR5CCR8CYP1A2IKBKB | |
| SCHEMBL14707165 | 0.67 | CCR1 (0.45) | CCR1CCR5CCR8CYP1A2IKBKB | |
| SCHEMBL12483324 | 0.65 | CCR1 (0.48) | CCR1CCR5CCR8CYP1A2IKBKB | |
| SCHEMBL7921134 | 0.65 | SMN1; SMN2 (0.43) | CCR1CCR5CCR8CYP1A2IKBKB | |
| SCHEMBL24611854 | 0.65 | CYP2A6 (0.55) | CCR1CCR5CCR8CYP1A2KDM4E | |
| SCHEMBL8312255 | 0.65 | CYP1A2 (0.42) | CCR1CCR5CCR8CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858904-B2 | Process for preparing large size isoxazoline particles | INTERVET INC. (JE) | 2024-01-02 | — | — | US | disclosed |
| US-20230310386-A1 | INJECTABLE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTERVET INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230233530-A1 | IMPLANTABLE ISOXAZOLINE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTERVET INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-11648238-B2 | Implantable isoxazoline pharmaceutical compositions and uses thereof | INTERVET INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11179372-B2 | Isoxazoline solution containing vitamin E for use with sanitized drinking water | INTERVET INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210354283-A1 | ISOXAZOLINE SOLUTION CONTAINING VITAMIN E FOR USE WITH SANITIZED DRINKING WATER | INTERVET INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210177808-A1 | INJECTABLE ISOXAZOLINE PHARMACEUTICAL COMPOSITIONS AND THEIR USE AGAINST PARASITE INFESTATION | INTERVET INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210161867-A1 | Implantable Isoxazoline Pharmaceutical Compositions and Uses Thereof | INTERVET INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-20200390748-A1 | Antiparasitic Pour-On Compositions | INTERVET INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200331867-A1 | Process for Preparing Large Size Isoxazoline Particles | INTERVET INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20190343808-A1 | ISOXAZOLINE SOLUTION CONTAINING VITAMIN E FOR USE WITH SANITIZED DRINKING WATER | INTERVET INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20180169073-A1 | ISOXAZOLINE SOLUTION CONTAINING VITAMIN E FOR USE WITH SANITIZED DRINKING WATER | INTERVET INC. (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177808-A1 | INJECTABLE ISOXAZOLINE PHARMACEUTICAL COMPOSITIONS AND THEIR USE AGAINST PARASITE INFESTATION | INA, MMP1, EPX | CCR1 2867/4885CCR5 818/4885CCR8 3389/4885 |
| US-11858904-B2 | Process for preparing large size isoxazoline particles | PDE8A, RPS4X, MRPS27 | CCR1 4258/4885CCR5 3050/4885CCR8 3991/4885 |
| US-11179372-B2 | Isoxazoline solution containing vitamin E for use with sanitized drinking water | PROC, EPX, CYP27B1 | CCR1 3662/4885CCR5 3132/4885CCR8 3718/4885 |
| US-20200331867-A1 | Process for Preparing Large Size Isoxazoline Particles | PDE8A, RPS4X, MRPS27 | CCR1 4258/4885CCR5 3050/4885CCR8 3991/4885 |
| US-20190343808-A1 | ISOXAZOLINE SOLUTION CONTAINING VITAMIN E FOR USE WITH SANITIZED DRINKING WATER | PROC, EPX, CYP27B1 | CCR1 3662/4885CCR5 3132/4885CCR8 3718/4885 |
| US-20230310386-A1 | INJECTABLE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CYP3A7, PDE8A, CYP4X1 | CCR1 1400/4885CCR5 161/4885CCR8 1205/4885 |
| US-20180169073-A1 | ISOXAZOLINE SOLUTION CONTAINING VITAMIN E FOR USE WITH SANITIZED DRINKING WATER | PROC, EPX, CYP27B1 | CCR1 3662/4885CCR5 3132/4885CCR8 3718/4885 |
| US-20230233530-A1 | IMPLANTABLE ISOXAZOLINE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CYP3A7, PIGS, CYP4X1 | CCR1 3839/4885CCR5 1314/4885CCR8 3990/4885 |
| US-20200390748-A1 | Antiparasitic Pour-On Compositions | PIGS, ARG1, ARG2 | CCR1 2552/4885CCR5 512/4885CCR8 3800/4885 |
| US-11648238-B2 | Implantable isoxazoline pharmaceutical compositions and uses thereof | CYP3A7, PIGS, CYP4X1 | CCR1 3839/4885CCR5 1314/4885CCR8 3990/4885 |
| US-20210161867-A1 | Implantable Isoxazoline Pharmaceutical Compositions and Uses Thereof | CYP3A7, PIGS, CYP4X1 | CCR1 3839/4885CCR5 1314/4885CCR8 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.